Screener
Icahn Enterprises IEP Pharma — Number Of Approved Therapies
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept iep:NumberOfApprovedTherapies.
The source filing: Icahn Enterprises’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:21 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056376
We conduct our Pharma segment through our wholly owned subsidiary, Vivus LLC, formerly Vivus, Inc. (“Vivus”). Vivus is a specialty pharmaceutical company with two approved therapies: one for chronic weight management and the other for the treatment of exocrine pancreatic insufficiency. In addition, Vivus has two product candidates in active clinical development and two product candidates in early-stage development.
Item 1. Financial Statements (Unaudited)
FAQ
- What is Icahn Enterprises's pharma — number of approved therapies?
- Icahn Enterprises (IEP) reported pharma — number of approved therapies of 2 in Q1 2026.
- How has Icahn Enterprises's pharma — number of approved therapies changed year-over-year?
- Icahn Enterprises's pharma — number of approved therapies decreased by 0.0% year-over-year, from 2 to 2.
- What does pharma — number of approved therapies mean?
- The total count of pharmaceutical products or therapies that have received regulatory approval for commercial sale and distribution. This metric serves as a key indicator of the segment's commercial maturity and its ability to successfully navigate the regulatory approval process.
Ask your AI about Icahn Enterprises's pharma — number of approved therapies.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude